Key highlights
- License agreement covers patent rights for using insulin-like growth factor 1 (IGF-1) to treat spasms
- ET-900 uses mecasermin, the active ingredient in Eton existing product INCRELEX
- Preclinical animal models demonstrated a 50 percent reduction in daily spasm counts
- Investigational New Drug application has been submitted to the FDA for a Phase 2 trial
- The program supports Eton strategic expansion into the pediatric neurology therapeutic area
What Happened
Eton Pharmaceuticals has officially launched the ET-900 development program following a licensing agreement with Baylor College of Medicine. This initiative focuses on evaluating mecasermin injection—a recombinant form of IGF-1—for children suffering from refractory epileptic spasms. The partnership follows preclinical research funded by CURE Epilepsy and the NIH, which indicated that impaired IGF-1 signaling may contribute to the development of these spasms. A research IND has already been submitted to the FDA, paving the way for an investigator-sponsored Phase 2 clinical study. Initial patient enrollment and dosing are currently projected to commence in the first quarter of 2027.
Significance
- The agreement grants Eton commercial rights to ET-900, reinforcing its pipeline in pediatric neurology
- Preclinical studies showed that IGF-1 therapy eliminated spasms in 20 percent of treated animal subjects
- Researchers suggest mecasermin may act as a replacement therapy for patients with structural brain abnormalities
- The program utilizes an active ingredient already commercialized by the company, potentially streamlining development
- Success in this indication would address a significant unmet need for patients resistant to current therapies
Business Overview
Headquartered in Deer Park, Illinois, Eton Pharmaceuticals is a specialty pharmaceutical company dedicated to rare disease treatments. The company focuses on the development, acquisition, and commercialization of products primarily for the pediatric market. Its portfolio includes INCRELEX, which shares the same active ingredient as the newly announced ET-900, as well as several recent additions to its neurology and infectious disease offerings. By targeting orphan indications with high clinical demand, the company aims to build a sustainable pipeline of specialized therapies that address gaps in the current standard of care for rare pediatric conditions.
Financial Context
- Eton reported record quarterly product sales of 37.6 million dollars in the second quarter of 2026
- Management has raised its full-year 2026 net revenue guidance to exceed 145 million dollars
- The company maintains a target Adjusted EBITDA margin of at least 35 percent for the current fiscal year
- Recent expansion activities include a 10.0 million dollar licensing deal for LIBERVANT and a 3.0 million dollar agreement for ASN-001
- Third-quarter 2026 financial results are scheduled for release on November 5, 2026
Up 22.4% since our story on 2 Nov: $52.18 when we broke it → $63.88 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $49.22 |
|---|---|
| 20 Oct | $50.19 |
| 21 Oct | $49.30 |
| 22 Oct | $50.02 |
| 23 Oct | $50.00 |
| 26 Oct | $50.17 |
| 27 Oct | $51.16 |
| 28 Oct | $51.80 |
| 29 Oct | $53.67 |
| 30 Oct | $52.18 |
| 2 Nov | $50.81 |
| 3 Nov | $50.95 |
| 4 Nov | $50.72 |
| 5 Nov | $47.15 |
| 6 Nov | $56.46 |
| 9 Nov | $64.35 |
| 10 Nov | $67.54 |
| 11 Nov | $68.40 |
| 12 Nov | $61.45 |
| 13 Nov | $63.93 |
| 16 Nov | $63.88 |
| Date | Announcement | Amount |
|---|---|---|
| 14 Oct 2026 | Exclusive U.S. licensing agreement with Aquestive Therapeutics for LIBERVANT buccal filmSource: thepharmaletter.com | $10.0 Million |
| 28 Sep 2026 | U.S. commercial availability and launch of IMPAVIDO (miltefosine) capsulesSource: ir.etonpharma.com | – |
| 13 Aug 2026 | Second quarter 2026 financial results with record product salesSource: ir.etonpharma.com | $37.6 Million |
| 05 Aug 2026 | Exclusive U.S. licensing agreement with Auson Pharmaceuticals for late-stage candidate ASN-001Source: SEC filing | $3.0 Million |
| 19 May 2026 | Exclusive U.S. commercialization agreement with Knight Therapeutics for IMPAVIDOSource: SEC filing | $4.2 Million |
Management commentary
“These spasms can have devastating and lifelong consequences for children and their families, and there remains a significant and urgent need for new therapeutic approaches due to high rates of resistance to current therapies.”
| Share price | $52.18 |
|---|---|
| Market cap | $1.5B |
| Revenue (annual) | $80M |
| P/E (TTM) | 130.4× |
| 1-month price change | +1.34% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Eton Pharmaceuticals, Inc. announcing the ET-900 development program and a license agreement with Baylor College of Medicine.
Track Eton Pharmaceuticals, Inc. live
Get the next Eton Pharmaceuticals, Inc. SEC filing seconds after it lands.




